Page last updated: 2024-12-10
meteneprost
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
meteneprost: 9-deoxo-9-methylene-PGEs are possible solution to PGE stability problem; stable in aqueous media from pH 1 to 14 & have biological properties similar to corresponding PGEs; cpd tested for use as early pregnancy terminater & has low incidence of nausea & gastrointestinal side effects; note that cpd is derivative of both PGE2 & PGF2alpha; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 5283060 |
CHEMBL ID | 3989772 |
CHEBI ID | 165325 |
SCHEMBL ID | 564226 |
MeSH ID | M0084951 |
Synonyms (44)
Synonym |
---|
meteneprost |
u-46785 |
61263-35-2 |
D02726 |
meteneprost (usan/inn) |
meteneprost [usan:inn] |
prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-16,16-dimethyl-9-methylene-, (5z,11alpha,13e,15r)- |
u 46785 |
meteneprostum [latin] |
(5z,11r,13e,15r)-11,15-dihydroxy-16,16-dimethyl-9-methylen-5,13-prostadiensaeure |
9-deoxo-16,16-dimethyl-9-methylene-pge2 |
u-46,785 |
9-deoxo-16,16-dimethyl-9-methyleneprostaglandin e2 |
meteneprostum |
7-(5,5-dimethyl-3-hydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl)-5-heptenoic acid |
(z)-7-((1r,2r,3r)-3-hydroxy-2-((e)-(3r)-3-hydroxy-4,4-dimethyl-1-octenyl)-5-methylenecyclopentyl)-5-heptenoic acid |
meteneprostum [inn-latin] |
5-heptenoic acid, 7-(5,5-dimethyl-3-hydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl)- |
9-deoxy-9-methylene-16,16-dimethyl -pge2 |
LMFA03010059 |
9-deoxy-9-methylene-16,16-dimethyl -prostaglandin e2 |
9-methylene-11r,15s-dihydroxy-16,16-dimethyl-5z,13e-prostadienoic acid |
(z)-7-[(1r,2r,3r)-3-hydroxy-2-[(e,3r)-3-hydroxy-4,4-dimethyloct-1-enyl]-5-methylidenecyclopentyl]hept-5-enoic acid |
CHEBI:165325 |
269eb4r1tv , |
unii-269eb4r1tv |
SCHEMBL564226 |
meteneprost [usan] |
meteneprost [mart.] |
9-deoxo-16,16-dimethyl-9-methyleneprostaglandin e(sub 2) |
(z)-7-[(1r,2r,3r)-3-hydroxy-2-[(e)-(3r)-3-hydroxy-4,4-dimethyl-1-octenyl]-5-methylenecyclopentyl]-5-heptenoic acid |
u 46,785 |
prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-16,16-dimethyl-9-methylene-, (5z,11.alpha.,13e,15r)- |
meteneprost [inn] |
9-deoxy-9-methylene-16,16-dimethyl prostaglandin e2 |
AC-31145 |
HMS3648H05 |
prosta-5,13-dien-1-oicacid,11,15-dihydroxy-16,16-dimethyl-9-methylene-,(5z,11a,13e,15r)- |
CHEMBL3989772 |
sr-01000946425 |
SR-01000946425-1 |
DTXSID001018145 |
Q27254077 |
AKOS040755477 |
Research Excerpts
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
"The effects of intravenous infusions of the stable prostaglandin analogue 9-deoxo-16,16-dimethyl-9-methylene-PGE2 (9-methylene-PGE2) in a dosage of 10 or 24 micrograms/min were studied in the consicious euhydrated, dehydrated, and hyperhydrated with the simultaneous administration of exogenous arginine vasopressin (AVP), sheep." | ( The prostaglandin-analogue-9-deoxo-16,16-dimethyl-9-methylene-PGE2 inhibits the antidiuretic effect of vasopressin (AVP) in the conscious sheep. Bygdeman, M; Christensen, NJ; Greén, K; Jonasson, H; Leksell, LG; Rundgren, M; Vesterqvist, O; Wallin, CJ, 1984) | 0.27 |
"5 ml/min) in the dosage of 20 micrograms/min for 2 h in conscious euhydrated man." | ( Water diuretic effect of intravenously administered 9-deoxo-16, 16-dimethyl-9-methylene-PGE2 in conscious man. Christensen, NJ; Leksell, LG; Vesterqvist, O; Wallin, CJ, 1984) | 0.27 |
"A comparative study was conducted to assess the relative efficacy and side effects of 2 dosage schedules using 9-deoxo-16,16-dimethyl-9-methylene PGE2alpha (prostaglandin) for 2nd-trimester abortion." | ( The vaginal administration of 9-deoxo-16,16-dimethyl-9-methylene PGE2 for second trimester abortion. Ballard, CA, 1981) | 0.26 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
Class | Description |
---|---|
long-chain fatty acid | A fatty acid with a chain length ranging from C13 to C22. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (43)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 36 (83.72) | 18.7374 |
1990's | 6 (13.95) | 18.2507 |
2000's | 1 (2.33) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 15.33
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (15.33) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 16 (34.78%) | 5.53% |
Reviews | 1 (2.17%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 29 (63.04%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |